Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts
2026-05-18·via All Articles on Seeking Alpha
Summary
The Trump administration’s recent cuts at the FDA have put the agency’s executive capacity under strain, which may lead to medicine shortages and less innovation.
Marty Makary’s successor as the new FDA commissioner thus faces a tough task.
The FDA’s ability to balance speed with safety helps explain why the US has a more innovative pharmaceutical sector than Europe.
CHOLTICHA KRANJUMNONG/iStock via Getty Images
By Diederik Stadig, Senior Economist, Healthcare & Technology
Executive summary
Marty Makary, the US Food and Drug Administration (FDA) commissioner, has been ousted just over a year into the role amid criticism from both inside and outside the
